MedTrace Logo

Doxycycline for Elbow Tendinopathy

NCT04686799 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-28

No results posted yet for this study

Summary

To evaluate the feasibility of subantimicrobial -dose (SD) doxycycline to improve outcomes of nonsurgical management of elbow tendinopathy via matrix metalloproteinase (MMP) inhibition as well as evaluate if participants will be compliant to with prescribed medication and exercise treatment. Our working hypothesis is that patients with elbow tendinopathy will be receptive to treatment with SD-doxycycline and compliant with the prescribed treatment.

Conditions

  • Lateral Epicondylitis
  • Lateral Epicondylitis, Left Elbow
  • Lateral Epicondylitis, Right Elbow
  • Lateral Epicondylitis, Unspecified Elbow
  • Lateral Epicondylitis (Tennis Elbow) Bilateral
  • Medial Epicondylitis
  • Medial Epicondylitis, Right Elbow
  • Medial Epicondylitis, Left Elbow

Interventions

DRUG

Doxycycline Hyclate 20 MG

Subjects will receive doxycycline 20 mg BID

Sponsors & Collaborators

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • Brett G Toresdahl, MD · Hospital for Special Surgery, New York

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2025-10-09
Completion
2025-10-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686799 on ClinicalTrials.gov